Science

Live blog: PolyBio’s Fall 2025 Symposium shares Long COVID and related disease research updates

Science

·

By

sick times

–

November 14, 2025

Leading Long COVID and related disease researchers are set to present updates to their work today at the PolyBio Research Foundation’s Fall 2025 Symposium. PolyBio supports some of the most highly-anticipated research projects in infection-associated chronic conditions (IACCs).
Research updates, November 11

Science

·

By

Miles W. Griffis

–

November 11, 2025

The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
Research updates, November 4

Science

·

By

Miles W. Griffis

–

November 4, 2025

The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
We need more at-home clinical trials for Long COVID. Here’s how we designed the largest one yet.

Commentary, Science

·

By

Julia Moore Vogel

–

October 30, 2025

We are now recruiting for the Long COVID Treatment Trial-Tirzepatide (LoCITT-T), which participants can complete entirely from bed.
Metformin has been shown to reduce the risk of Long COVID. Why isn’t it more widely used?

Health, Science

·

By

Rachel Fairbank

–

October 28, 2025

Recent studies add evidence to a prior phase 3 clinical trial, suggesting that taking the diabetes drug during acute COVID-19 reduces the risk of long-term symptoms.
Research updates, October 28

Science

·

By

Miles W. Griffis

–

October 28, 2025

A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
Research updates, October 21

Science

·

By

Miles W. Griffis

–

October 21, 2025

A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
Nicotine patches help relieve symptoms in some people with Long COVID. Can the science behind it lead to future therapies?

Health, Science

·

By

Astra Lincoln

–

October 17, 2025

Some people with Long COVID and the providers who were treating them wondered if nicotine, delivered by a mechanism other than cigarettes, might help with the chronic disease. For the next several years, white papers used anecdotal evidence to expand on that initial hypothesis.
Research updates, October 14

Science

·

By

Miles W. Griffis

–

October 14, 2025

A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
Getting diagnosed with hypermobility can help some people with Long COVID. Upcoming guidelines may make it easier.

Health, Science

·

By

Margot Armbruster

–

October 7, 2025

Current diagnostic criteria for hypermobile Ehlers-Danlos syndrome (hEDS), a common comorbidity of Long COVID, are restrictive. The Ehlers-Danlos Society is developing new hEDS criteria that will be released in 2026.